INTELGENX TECHS CORP - IGXT STOCK NEWS

IntelGenx Technologies Corp. (TSXV: IGX, OTCQB: IGXT) has announced an amended secured loan agreement with atai Life Sciences, providing $3 million loans maturing on January 5, 2024. The agreement also extends existing loans of $2.5 million to the same maturity date. Additionally, IntelGenx has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange, pending compliance with requirements. This move will enhance visibility among institutional investors, as noted by CEO Dr. Horst G. Zerbe.

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) announced the launch of RIZAPORT® in Spain, its proprietary oral thin film formulation for treating acute migraines. This marks the first product utilizing its VersaFilm® technology to hit the global market. RIZAPORT is designed for patients who struggle with swallowing pills, addressing a significant segment of the migraine population, where approximately 80% experience migraine-related nausea. The European migraine drug market is expected to grow from over $1 billion in 2019 to nearly $1.5 billion by 2024.

IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) announced the successful shipment of CBD Filmstrips to support the launch of Heritage Cannabis's "CB4 Control" product in Canada. Produced under Canadian GPP conditions, these filmstrips are registered with Health Canada and represent IntelGenx's shift from development to commercial operations. CEO Dr. Horst G. Zerbe expressed enthusiasm for the partnership with Heritage Cannabis, while Umar Syed highlighted the innovative delivery technology of the Versafilm® platform, promising rapid and better absorption for consumers.

IntelGenx Technologies Corp. (TSXV: IGX, OTCQB: IGXT) successfully closed a private placement offering of 8% convertible notes due July 31, 2025, raising approximately U.S.$2.1 million. The notes will have a six-month conversion period at a price of U.S.$0.40 per share. Cantone Research acted as the placement agent, receiving a cash commission of approximately U.S.$199,525 and non-transferable warrants for 613,000 shares. The funds will primarily support IntelGenx's Montelukast study, with conditional approval for share listing on TSXV pending compliance with requirements.

IntelGenx Technologies Corp. (TSX V:IGX, OTCQB:IGXT) announced its Q2 2021 financial results, reporting revenues of $162,000, up 286% from $42,000 in Q2 2020. The net comprehensive loss grew to $2.5 million, compared to $1.3 million a year earlier. Adjusted EBITDA loss reached $1.7 million. Key developments include a $2.1 million investment in convertible notes for a Montelukast study and a $12.3 million investment from ATAI Life Sciences, which now owns 25% of IntelGenx. The company maintains $12.1 million in cash and short-term investments.

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) announced the appointments of Dr. Srinivas G. Rao and Frank Stegert to its Board of Directors, increasing its size from six to eight members. Dr. Rao serves as Chief Scientific Officer at ATAI Life Sciences, and Mr. Stegert is Vice President of Investment Management and Operations at the same company. Dr. Rao will join the Compensation Committee, while Mr. Stegert will serve on the Corporate Governance and Nominations Committee. Both will serve until the 2022 annual shareholders' meeting.

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) will release its second quarter 2021 financial results post-market on August 4, 2021. A conference call led by Dr. Horst G. Zerbe and Mr. Andre Godin will follow at 4:30 p.m. ET. The call will include a business update and will be accessible via telephone and webcast. IntelGenx specializes in drug delivery through innovative pharmaceutical films aimed at addressing unmet medical needs. For further details, visit their website.

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) has secured U.S.$2.1 million in subscriptions for 8% convertible notes due July 31, 2025. The notes, convertible into common stock at U.S.$0.40 per share, are set to close by July 30, 2021, pending regulatory approvals. Proceeds from this offering will fund the Company’s Montelukast study. IntelGenx specializes in drug delivery systems, aimed at addressing unmet medical needs through innovative pharmaceutical films.

IntelGenx Corp. (TSX-V:IGX) announced a Materials Transfer Agreement with a global veterinary health company to evaluate its VetaFilm™ platform in cats. Upon successful evaluation, commercial negotiations will follow. CEO Dr. Horst G. Zerbe emphasized that this agreement is a significant step in establishing VetaFilm™ as a new standard in veterinary drug delivery. IntelGenx focuses on developing and manufacturing pharmaceutical films, with technologies aimed at addressing unmet medical needs.